Analysis
Laboratory validation is underway for an antimicrobial peptide candidate prioritized through Google DeepMind’s agent-assisted search. Its activity remains a prediction. The company’s October 15 walkthrough reports no demonstrated antimicrobial efficacy or clinical safety finding.
Researchers direct the questions while Antigravity coordinates database research. The account, co-authored by Lucy J. Colwell and four others, describes a search drawing on functional predictions, sequence comparisons, structural evidence and genomic context.
Assembling those materials gives researchers a case to examine before committing further work to a candidate. Its usefulness depends partly on whether the reasoning can be followed back to the evidence. A sequence comparison and a model prediction contribute different kinds of support; combining them in a readable explanation does not make them interchangeable.
The record becomes especially valuable when an experiment disappoints. Keeping negative results alongside the original rationale would help researchers see which assumptions survived testing and which need revision. It would also make unsuccessful leads visible in any later accounting of the workflow’s value.
For now, the search has produced a candidate for testing and an explanation of its selection. Whether the process saves research time remains unresolved, including the time people spend checking its work. Laboratory measurements must establish whether the predicted activity holds up and merits further investigation.
Source: Google Antigravity: Accelerating Antimicrobial Peptide Search · 2026-10-15 · Primary source context · attributed account